Shares of vTv Therapeutics Inc (NASDAQ:VTVT) have been given an average rating of “Hold” by the seven brokerages that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $6.75.

A number of brokerages recently weighed in on VTVT. Northland Securities restated a “hold” rating and set a $3.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, February 27th. Zacks Investment Research upgraded vTv Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Saturday, February 9th.

In related news, major shareholder Ronald O. Perelman purchased 815,217 shares of vTv Therapeutics stock in a transaction on Wednesday, January 16th. The shares were purchased at an average price of $1.84 per share, for a total transaction of $1,499,999.28. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders acquired a total of 4,076,085 shares of company stock worth $7,499,996 in the last quarter. Corporate insiders own 2.00% of the company’s stock.

An institutional investor recently bought a new position in vTv Therapeutics stock. D. E. Shaw & Co. Inc. bought a new stake in vTv Therapeutics Inc (NASDAQ:VTVT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 70,300 shares of the biotechnology company’s stock, valued at approximately $186,000. D. E. Shaw & Co. Inc. owned 0.17% of vTv Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 1.26% of the company’s stock.

Shares of VTVT stock opened at $2.31 on Friday. The firm has a market cap of $97.64 million, a P/E ratio of -3.35 and a beta of -3.72. vTv Therapeutics has a twelve month low of $0.65 and a twelve month high of $6.09.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Recommended Story: What is a Futures Contract?

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with's FREE daily email newsletter.